Past treatments for
serious medical retinal diseases such as agerelated
macular degeneration or central retinal vein occlusion were largely
limited to ablative laser or challenging surgical intervention. The
approval of Macugen, an aptamer specific for VEGF 165, in 2004 heralded
the beginning of a new pharmacological/ biological era for retinal
therapy. The successful development of Macugen was made possible by the
identification of vascular endothelial growth factor as an important
contributor to neovascular complications of so-called wet AMD.
Lucentis, an FAB2 portion of anti-VEGF antibody, was approved for wet
AMD in 2006, demonstrating not only stabilization of vision in wet AMD
patients, but also the improvement of vision in a substantial proportion
Even before Lucentis was approved, investigators were exploring the
therapeutic use of another anti-VEGF biologic, Avastin, a full anti-VEGF
antibody approved for oncology, for the treatment of wet AMD with
positive results reported in multiple studies. Each of these
“antibody-like” anti-VEGF products is effective in providing therapeutic benefit in patients. However, each of these products requires monthly
or at least frequent intravitreal administration for maximal patient
benefit, a requirement that places a large burden on patients, their
families and clinicians.
A Different Approach
Gene therapy offers a different approach to ophthalmic therapies that
can offer significant benefits to patients with regard to safety,
efficacy and convenience. The current interest in ocular gene therapy
has been stimulated by early success in a gene therapy under
investigation for an inherited blinding disorder, Leber’s congenital
amaurosis type 2 (LCA2). First described in the 19th century, LCA2 is
associated with an abnormality in the gene RPE65, which normally codes
for a protein required for photoreceptor cell function. It is also
associated with a mutation in the RPE65 gene in dogs in the late 1990s.
Successful AAV RPE65 gene therapy in the dog model set the stage for
human clinical trials.
Clinical trials in LCA2 began in 2007, with three different clinical
trials being conducted simultaneously. The animal studies and the
clinical studies employed the sub-retinal route of administration as
this was the only known route for delivery to the cells of the RPE.
Gene therapy clinical trials are routinely carried out in patients, as
opposed to normal volunteers. Demonstration of safety is the primary
objective of early-phase trials. The first subjects were young adults
with LCA2 who were legally blind. Remarkably, in addition to
demonstration of safety to date, subjects in each of the different
clinical trials experienced some improvement in vision, ranging from an
improvement in ability to navigate to increased sensitivity to light.
The LCA2 clinical trials are continuing with the hope and promise of
bringing LCA2 gene therapy to approval and to the benefit of affected
AAV Gene Therapy
Building on the success of LCA2 gene therapy, AAV, or adeno-associated
virus, gene therapy is being contemplated and planned for other
monogenic blinding disorders. In addition, gene therapy technology is
being explored for additional ocular disorders beyond monogenic
disorders. Genzyme is attempting to combine the proven mechanism of
anti-VEGF therapy with the attractive features of AAV gene therapy for
the benefit of wet-AMD patients.
As mentioned above, the benefits of VEGF neutralization have been proven
clinically in several trials. However, frequent, if not monthly,
intraocular injections are required for maximum patient benefit. The
therapeutic agent under evaluation in the Genzyme clinical trial is AAV2
sFLT01, a gene therapy vector encoding an anti-VEGF protein based on
VEGF receptor 1. This modality offers the potential of significant
treatment durability, perhaps in the range of a year or greater. The
Genzyme approach is to employ the intravitreal route of administration
of the AAV2 sFLT01 vector, as opposed to the sub-retinal route employed
in the LCA2 trials. Sub-retinal surgery for vector administration for
blinding disorders with no therapeutic option can obviously be done, but
would best be avoided in wet AMD patients, if possible. Moreover,
retinal specialists who are treating patients with anti-VEGF biologics
are routinely utilizing the intravitreal route of administration.
To prepare for AAV2 sFLT01 clinical trials, an extensive series of
efficacy and safety testing in animals was completed in rodents and in
non-human primates. Key findings in non-human primates were the
demonstration of expression of the sFLT01 anti-VEGF protein for more
than a year and efficacy in the challenging laser CNV model.
A multicenter, non-controlled, dose-escalating Phase 1 safety trial is
under way. Patients with advanced exudative AMD (fibrosis or disciform
scarring with presence of intraretinal or subretinal fl uid) are
eligible. Patients are treated with a single intravitreal injection of
AAV2- sFLT01 in cohorts of three subjects, with an additional three
patients enrolled if evidence of toxicity is seen in one of the first
three. Toxicity in two or more patients in a single cohort of up to six
patients would lead to the maximum tolerated dose. At this point,
additional patients with less-severe exudative AMD would be enrolled in a
second phase of the trial, looking primarily at safety, but with
efficacy being a secondary outcome. Multiple safety parameters are
being assessed in the trial. Surrogate endpoints for efficacy include
retinal thickness as measured by ocular coherence tomography, as well as
direct measurement of expression of the SFLT01 protein in the aqueous
humor. Initial results of the trial should be available in early 2012.
Dr. Wadsworth is vice president of gene therapy and regenerative science, Genzyme Corp., Cambridge, Mass. Dr. Heier is a vitreoretinal specialist at Ophthalmic Consultants of Boston, an assistant professor in ophthalmology at Tufts Medical School, and co-director of the Ophthalmic Consultants of Boston/Tufts Medical School Vitreoretinal Fellowship.